Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Premier Biosoft, and Artel

PerkinElmer this week said it has launched the Geliance family of gel imaging products. Geliance offers optical performance, easy-to-use hardware and software to customers who need fluorescence and chemiluminescence imaging solutions, the company said in a statement. The Geliance 200 is designed for 1D fluorescence imaging, the Geliance 600 is designed for chemiluminescence imaging.
PerkinElmer also announced the release of its PhotoKinesis accessory to the UltraVIEW Live Cell Imaging System for fluorescence recovery after photobleaching, and the Spotlight 400 FT-IR imaging system, which enables laboratories to run more samples. The system provides faster data collection and longer unattended operating time, the company said.

Premier Biosoft this week launched SimGlycan, a tool to predict glycan structure by matching the experimental mass spec profile with the company’s database of theoretical fragmentation of 7,000 glycans.
Premier said that each structure is scored to help researchers closely match experimental data. Other information such as glycan class, reaction, pathway, and enzyme is also made available.

Artel will be launching its Liquid Handler Performance Verification service in January at Lab Automation 2007 in Palm Springs, Calif. LHPV will give laboratories third-party, documented assessment of the accuracy and precision of their equipment, the company said.

The new service will provide performance results traceable to national standards, the company said, and performances will be checkable for serial dilution dispensing and delivery of non-aqueous reagents. All makes and models of liquid handlers, from single to 384-channel devices, will be verifiable.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.